title: Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes.
abstract: OBJECTIVE
  To report the vision outcome following intravitreal triamcinolone acetonide (IVTA) as adjunctive therapy in four eyes of two patients with paraneoplastic autoimmune optic neuritis and vitreitis related to CRMP (Collapsin-Response-Mediator Protein)-5-IgG.
  
  
  METHODS
  Retrospective case series.MethodsChart review of four eyes.
  
  
  RESULTS
  Preoperative visions were: patient 1, 20/50 OD, 20/25 OS; patient 2, counting fingers (CF) at two feet OD, and CF at three feet OS. At last follow-up, the postoperative visions were 20/40, 20/50 and 20/200, 20/60, respectively. All signs of optic disc swelling and vitreitis had abated.
  
  
  CONCLUSIONS
  Use of IVTAin paraneoplastic autoimmune optic neuritis and vitreitis related to CRMP-5-IgG was followed by a marked decrease in inflammation and stabilization or improvement of vision. These observations support this form of adjunctive therapy in patients whose intraocular pathology is attributed to paraneoplastic autoimmunity.
authors.affiliation: Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN, USA.
authors.forename: J
authors.initials: J
authors.lastname: Pulido
authors.forename: S A
authors.initials: SA
authors.lastname: Cross
authors.forename: V A
authors.initials: VA
authors.lastname: Lennon
authors.forename: J
authors.initials: J
authors.lastname: Pulido
authors.forename: D
authors.initials: D
authors.lastname: Swanson
authors.forename: M
authors.initials: M
authors.lastname: Muench
authors.forename: D H
authors.initials: DH
authors.lastname: Lachance
mesh_terms: D000368:Aged; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy* / Q000276:immunology; D005128:Eye Diseases / Q000188:drug therapy / Q000276:immunology; D005260:Female; D006801:Humans; D006867:Hydrolases; D007074:Immunoglobulin G / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008869:Microtubule-Associated Proteins; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000276:immunology; D009898:Optic Disk / Q000276:immunology; D009902:Optic Neuritis / Q000188:drug therapy* / Q000276:immunology; D010257:Paraneoplastic Syndromes / Q000188:drug therapy* / Q000276:immunology; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014822:Vitreous Body
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D008869:Microtubule-Associated Proteins; D009419:Nerve Tissue Proteins; C415087:DPYSL5 protein, human; D006867:Hydrolases; D014222:Triamcinolone Acetonide